A multi-national report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up*

Dagan, Roi, Lo, Simon S., Redmond, Kristin J., Poon, Ian, Foote, Matthew C., Lohr, Frank, Ricardi, Umberto and Sahgal, Arjun (2016) A multi-national report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up*. Acta Oncologica, 55 5: 633-637. doi:10.3109/0284186X.2015.1118659


Author Dagan, Roi
Lo, Simon S.
Redmond, Kristin J.
Poon, Ian
Foote, Matthew C.
Lohr, Frank
Ricardi, Umberto
Sahgal, Arjun
Title A multi-national report on stereotactic body radiotherapy for oligometastases: patient selection and follow-up*
Journal name Acta Oncologica   Check publisher's open access policy
ISSN 1651-226X
0284-186X
Publication date 2016-04-04
Year available 2016
Sub-type Article (original research)
DOI 10.3109/0284186X.2015.1118659
Open Access Status Not Open Access
Volume 55
Issue 5
Start page 633
End page 637
Total pages 5
Place of publication Abingdon, Oxfordshire, United Kingdom
Publisher Taylor & Francis
Collection year 2017
Language eng
Formatted abstract
Aims: Stereotactic body radiotherapy (SBRT) for oligometastases is increasingly used with few evidenced-based guidelines. We conducted a survey to determine patient selection and follow-up practice patterns.

Materials and methods: Seven institutions from US, Canada, Europe, and Australia that recommend SBRT for oligometastases participated in a 72-item survey. Levels of agreement were categorized as strong (6–7 common responses), moderate (4–5), low (2–3), or no agreement.

Results: There was strong agreement for recommending SBRT for eradication of all detectable oligometastases with most members limiting the number of metastases to five (range 2–5) and three within a single organ (range 2–5). There was moderate agreement for recommending SBRT as consolidative therapy after systemic therapy. There was strong agreement for requiring adequate performance status and no concurrent chemotherapy. Additional areas of strong agreement included staging evaluations, primary diagnosis, target sites, and follow-up recommendations. Several differences emerged, including the use of SBRT for sarcoma oligometastases, treatment response evaluation, and which imaging should be performed during follow-up.

Conclusion: Significant commonalities and variations exist for patient selection and follow-up recommendations for SBRT for oligometastases. Information from this survey may serve to help clarify the current landscape.
Keyword Oligometastases
Stereotactic body radiotherapy (SBRT)
Metastatic disease
Solid tumor
Follow-up and response assessment
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 26 Apr 2016, 01:52:07 EST by System User on behalf of Learning and Research Services (UQ Library)